Pharmaceutical Manufacturing and Formulation

The contract requires the manufacture of 600 mg extended-release guaifenesin tablets, encompassing all stages from active pharmaceutical ingredient sourcing through final batch release testing. All activities must strictly adhere to FDA regulatory standards and Department of Defense Medical Supply Chain Pharmaceutical FSA protocols, ensuring product safety, potency, and consistency. The work includes formulation development, quality control testing, and documentation compliant with current Good Manufacturing Practices, with final delivery directed to Fort Stewart, Georgia, under the specified zip code. This is a subcontract opportunity under NAICS code 325412, with a response deadline of May 18, 2026, and was posted on May 11, 2026. The contracting entity is the Department of Defense through its Medical Supply Chain Pharmaceutical FSA, and all performance must align with the DLA’s requirements for pharmaceutical procurement. The contract emphasizes end-to-end responsibility for the production cycle, including validated manufacturing processes and release criteria meeting federal pharmaceutical standards, with no set-aside provisions specified.